In conclusion, our integrative transcriptomic and immunogenomic analyses define the molecular and immune landscape of ABC DLBCL and identify MAPK10 and CCL18 as potential prognostic biomarkers. The gene discussed is CCL18; the disease is diffuse large B-cell lymphoma.